DGIdb - ADALIMUMAB Drug Record

ADALIMUMAB chembl:CHEMBL1201580 ApprovedImmunotherapy

Alternate Names:

MSB-11022
CT-P17
D2E7
MSB11022
ZRC3197
BI695501
FKB-327
FKB327
LU200134
GP2017
AVT-02
HLX03
ADALIMUMAB
ADALIMUMAB (GENETICAL RECOMBINATION)
ADALIMUMAB BETA
HLX-03
LU-200134
M923
HUMIRA
ZRC-3197
HUMIRA®
IG GAMMA-1 CHAIN C REGION
drugbank:00051
chemidplus:331731-18-1
rxcui:327361
chembl:CHEMBL1201580

Drug Info:

Year of Approval	2002
Drug Class	antirheumatic agents
FDA Approval	approved
Drug Class	monoclonal antibody
Drug Indications	antiinflammatory agent,DMARD

(2 More Sources)

Publications:

Deželak M et al., 2016, A Prospective Pharmacogenomic Study of Crohn's Disease Patients during Routine Therapy with Anti-TNF-α Drug Adalimumab: Contribution of ATG5, NFKB1, and CRP Genes to Pharmacodynamic Variability., OMICS
Iwaszko M et al., 2016, Influence of CD94 and NKG2A variants on susceptibility to rheumatoid arthritis and efficacy of anti-TNF treatment., Joint Bone Spine
Song GG et al., 2015, Association between TNF-α (-308 A/G, -238 A/G, -857 C/T) polymorphisms and responsiveness to TNF-α blockers in spondyloarthropathy, psoriasis and Crohn's disease: a meta-analysis., Pharmacogenomics
Tong Q et al., 2013, Association of TNF-α polymorphism with prediction of response to TNF blockers in spondyloarthritis and inflammatory bowel disease: a meta-analysis., Pharmacogenomics
Tong Q et al., 2012, TNF-α -857 and -1031 polymorphisms predict good therapeutic response to TNF-α blockers in Chinese Han patients with ankylosing spondylitis., Pharmacogenomics
Lacruz-Guzmán D et al., 2013, Influence of polymorphisms and TNF and IL1β serum concentration on the infliximab response in Crohn's disease and ulcerative colitis., Eur J Clin Pharmacol
Zeng Z et al., 2013, Association between tumor necrosis factor-α (TNF-α) promoter -308 G/A and response to TNF-α blockers in rheumatoid arthritis: a meta-analysis., Mod Rheumatol
Daïen CI et al., 2012, TGF beta1 polymorphisms are candidate predictors of the clinical response to rituximab in rheumatoid arthritis., Joint Bone Spine
O'Rielly DD et al., 2009, TNF-alpha-308 G/A polymorphism and responsiveness to TNF-alpha blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis., Pharmacogenomics J
Maxwell JR et al., 2008, Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis., Hum Mol Genet
Marotte H et al., 2008, Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor., Arthritis Rheum
Guis S et al., 2007, Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis., Arthritis Rheum
Cuchacovich M et al., 2006, Tumour necrosis factor (TNF)alpha -308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis., Scand J Rheumatol
Lee YH et al., 2006, Association of TNF-alpha -308 G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis., Rheumatol Int
Seitz M et al., 2007, The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients., Rheumatology (Oxford)
Mugnier B et al., 2003, Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis., Arthritis Rheum
Louis E et al., 2002, A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism., Scand J Gastroenterol
Bang et al., 2004, Adalimumab: a review of its use in rheumatoid arthritis., BioDrugs
Aguillón et al., 2003, [New immunological weapons for medicine in the 21st Century: biological therapy based on the use of the latest generation monoclonal antibodies]., Rev Med Chil
Klinkhoff, 2004, Biological agents for rheumatoid arthritis: targeting both physical function and structural damage., Drugs
Flendrie et al., 2003, Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis., Ann. Rheum. Dis.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Lorenz, 2002, Technology evaluation: adalimumab, Abbott laboratories., Curr. Opin. Mol. Ther.
Iwaszko M et al., 2015, Polymorphisms within the human leucocyte antigen-E gene and their associations with susceptibility to rheumatoid arthritis as well as clinical outcome of anti-tumour necrosis factor therapy., Clin Exp Immunol
Mendrinou E et al., 2017, FCGR3A-V158F polymorphism is a disease-specific pharmacogenetic marker for the treatment of psoriasis with Fc-containing TNFα inhibitors., Pharmacogenomics J
Dávila-Fajardo CL et al., 2015, FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis., Pharmacogenomics
Montes A et al., 2014, Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis., Pharmacogenet Genomics
Julià M et al., 2013, The role of Fcγ receptor polymorphisms in the response to anti–tumor necrosis factor therapy in psoriasis A pharmacogenetic study., JAMA Dermatol
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Pappas DA et al., 2013, Association of rheumatoid arthritis risk alleles with response to anti-TNF biologics: results from the CORRONA registry and meta-analysis., Inflammation
Cui J et al., 2010, Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy., Arthritis Rheum
Repnik K et al., 2016, Transferrin Level Before Treatment and Genetic Polymorphism in HFE Gene as Predictive Markers for Response to Adalimumab in Crohn's Disease Patients., Biochem Genet
Ovejero-Benito MC et al., 2018, Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis., Pharmacogenomics
Morales-Lara MJ et al., 2012, Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis., Joint Bone Spine
Dávila-Fajardo CL et al., 2014, Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome., Pharmacogenet Genomics
Koder S et al., 2015, Genetic polymorphism in ATG16L1 gene influences the response to adalimumab in Crohn's disease patients., Pharmacogenomics

ADALIMUMAB ATG16L1

Interaction Score: 7.27

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25712183

Sources:
PharmGKB
ADALIMUMAB HFE

Interaction Score: 7.27

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27115882

Sources:
PharmGKB
ADALIMUMAB ATG5

Interaction Score: 7.27

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27096233

Sources:
PharmGKB
ADALIMUMAB IVL

Interaction Score: 3.64

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29192552

Sources:
PharmGKB
ADALIMUMAB TF

Interaction Score: 3.64

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27115882

Sources:
PharmGKB
ADALIMUMAB FCGR2A

Interaction Score: 3.64

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27044681 25823785 24667440 24048425 17016423 17139284

Sources:
PharmGKB
ADALIMUMAB TRAF1

Interaction Score: 2.42

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23007924

Sources:
PharmGKB
ADALIMUMAB CRP

Interaction Score: 2.42

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27096233

Sources:
PharmGKB
ADALIMUMAB TNFRSF1A

Interaction Score: 1.82

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22480748

Sources:
PharmGKB
ADALIMUMAB ATP5F1E

Interaction Score: 1.82

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26307125

Sources:
PharmGKB
ADALIMUMAB KLRD1

Interaction Score: 1.82

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26453102

Sources:
PharmGKB
ADALIMUMAB TNF

Interaction Score: 1.39

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction TNF-alpha inhibitor

Direct Interaction yes

Trial Name Humira

PMIDs:
26244882 24192118 23057546 22960943 22760475 22129793 19365401 18713756 18438841 18050183 17343250 16909270 16720636 12847678 12190096 15046527 15022409 15200343 14532145 11752352 12044041

Sources:
TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD
ADALIMUMAB PTPRC

Interaction Score: 0.91

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23007924 20309874

Sources:
PharmGKB
ADALIMUMAB HLA-E

Interaction Score: 0.91

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ADALIMUMAB FCGR3A

Interaction Score: 0.76

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17016423 17139284 27044681 24048425

Sources:
PharmGKB
ADALIMUMAB IL6

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24253594

Sources:
PharmGKB
ADALIMUMAB HLA-DRB1

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB

TEND: ADALIMUMAB
- Version: 01-August-2011
Alternate Names:

ADALIMUMAB Primary Drug Name

Drug Info:

Drug Class antirheumatic agents

Year of Approval 2002

Publications:
TdgClinicalTrial: ADALIMUMAB
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antiinflammatory agent,DMARD

Drug Class monoclonal antibody

FDA Approval approved

Publications:

PharmGKB: adalimumab

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Iwaszko M et al., 2016, Influence of CD94 and NKG2A variants on susceptibility to rheumatoid arthritis and efficacy of anti-TNF treatment., Joint Bone Spine

Iwaszko M et al., 2015, Polymorphisms within the human leucocyte antigen-E gene and their associations with susceptibility to rheumatoid arthritis as well as clinical outcome of anti-tumour necrosis factor therapy., Clin Exp Immunol

Ovejero-Benito MC et al., 2018, Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis., Pharmacogenomics

TTD: Adalimumab
- Version: 2020.06.01
Alternate Names:

D0K5KS TTD Drug ID

Drug Info:

Publications:
ChemblInteractions: CHEMBL1201580
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1201580
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Mechanism of Interaction	TNF-alpha inhibitor
Direct Interaction	yes
Trial Name	Humira

antibody (inhibitory)
inhibitor (inhibitory)

ADALIMUMAB Drug Record

ADALIMUMAB chembl:CHEMBL1201580 ApprovedImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25712183

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27115882

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27096233

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29192552

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27115882

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27044681 25823785 24667440 24048425 17016423 17139284

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23007924

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27096233

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22480748

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26307125

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26453102

Sources: PharmGKB

Interaction Types & Directionality: antibody (inhibitory) inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction TNF-alpha inhibitor Direct Interaction yes Trial Name Humira

PMIDs: 26244882 24192118 23057546 22960943 22760475 22129793 19365401 18713756 18438841 18050183 17343250 16909270 16720636 12847678 12190096 15046527 15022409 15200343 14532145 11752352 12044041

Sources: TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23007924 20309874

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17016423 17139284 27044681 24048425

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24253594

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

TEND: ADALIMUMAB

Alternate Names: ADALIMUMAB Primary Drug Name

Drug Info: Drug Class antirheumatic agents Year of Approval 2002

Publications:

TdgClinicalTrial: ADALIMUMAB

Alternate Names:

Drug Info: Drug Indications antiinflammatory agent,DMARD Drug Class monoclonal antibody FDA Approval approved

Interaction Types & Directionality:

n/a

PMIDs:
25712183

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27115882

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27096233

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29192552

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27115882

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27044681 25823785 24667440 24048425 17016423 17139284

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
23007924

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27096233

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22480748

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26307125

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26453102

Sources:
PharmGKB

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction TNF-alpha inhibitor

Direct Interaction yes

Trial Name Humira

PMIDs:
26244882 24192118 23057546 22960943 22760475 22129793 19365401 18713756 18438841 18050183 17343250 16909270 16720636 12847678 12190096 15046527 15022409 15200343 14532145 11752352 12044041

Sources:
TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

Interaction Types & Directionality:

n/a

PMIDs:
23007924 20309874

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
17016423 17139284 27044681 24048425

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24253594

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Alternate Names:

ADALIMUMAB Primary Drug Name

Drug Info:

Drug Class antirheumatic agents

Year of Approval 2002

Drug Info:

Drug Indications antiinflammatory agent,DMARD

Drug Class monoclonal antibody

FDA Approval approved

Alternate Names:

D0K5KS TTD Drug ID